Transplant recipients represent a group at high risk for NMS since exhaustion and multiple medical illnesses, frequently seen in post-transplantation patients, are considered to be risk factors for NMS. 5 However, NMS is relatively difficult to identify in this setting because of the agranulocytosis and fever that follow BMT, and also the neurologic symptoms that occasionally occur as adverse effects of immunosuppressants. 6 Here, we describe a patient with NMS following BMT successfully treated after early diagnosis.
A 52-year-old woman with acute myeloid leukemia (FAB M0) underwent HLA-matched BMT. Before transplantation she had been treated with six courses of cytarabine and aclarubicin hydrochloride. She had no history of central nervous system disease except for depressive symptoms first noted a few months before BMT. BMT was carried out following conditioning with cyclophosphamide (60 mg/kg), thiotepa (200 g/m 2 ) on 2 consecutive days and total body irradiation (12 Gy in four 3 Gy doses on 4 consecutive days). Tacrolimus hydrate (1.2 mg/day) was given as prophylaxis against GVHD beginning on the day before transplantation. The patient had been depressed for 4 months before BMT and was diagnosed as adjustment disorder with mixed anxiety and depressed mood according to the forth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 7 Amitriptyline hydrochloride (50 mg/day) was started 16 days before transplantation. At the time of transplantation neurologic examination was normal, although anxiety and depression were still present. Amitriptyline hydrochloride was continued for 4 days after transplantation. When she became delirious, haloperidol (10 mg/day) was added. Within 48 h the patient became febrile (39.5°C) and developed tremors, rigidity in the upper extremities and fluctuating consciousness levels. On post-transplant day 6, in addition to the continuing fever, she developed generalized rigidity, tachycardia, hypertension, and rhabdomyolysis (creatine phosphokinase, 538 U/l; normal, Ͻ160). The serum creatinine concentration was 1.73 mg/dl. We diagnosed the patient as probable NMS according to the criteria of Pope et al, 1 although following BMT granulocytes were too few to be counted. Haloperidol and tacrolimus hydrate were discontinued. Cyclosporine (100 mg/day) and methylprednisolone (125 to 500 mg/day) were initiated as GVHD prophylaxis. Within the next 4 days the fever, tremor, hypertension, and tachycardia all improved. Within the next 12 days the disturbed consciousness and rigidity resolved, but low-grade fever continued. Subsequently, the creatine phosphokinase gradually rose to reach 2088 U/l on post-transplant day 19, returning to normal on day 25. No evidence of infections, endocrinopathies, or cerebrovascular events was noted during the febrile episode.
This patient developed NMS after BMT but improved after discontinuation haloperidol, a neuroleptic drug known to be associated with NMS. NMS complicating BMT has only been reported by Garrido and Chauncy. 8 According to the diagnostic criteria listed by Caroff and Mann, 5 NMS develops within 7 days after treatment with neuroleptics. In our patient, clinical symptoms of NMS developed within 48 h after commencing haloperidol. Characteristic NMS symptoms were present, except for the absence of leukocytosis and autonomic manifestations, such as hyperhidrosis. Granulocytes were too few to count, and sweating was difficult to assess after the preparatory regimen for BMT. We diagnosed our patient as probable NMS according to the diagnostic criteria, 1 which have been widely used. Clinical symptoms of NMS resolved after discontinuation of the causative drug.
Levinson and Simpson 9 questioned the concept of NMS as a single entity, and suggested that in most cases a specific medical cause of fever could be found. Although NMS is a form of drug-induced hyperthermia separate from extrapyramidal symptoms with fever, this distinction can present a difficult diagnostic challenge. 5 As in our case, NMS can be difficult to diagnose in the presence of multiple complicating factors such as agranulocytosis, GVHD, immunosuppression and so on, but the diagnosis is highly important given the risk of death. 4, 10 Given the somewhat atypical clinical course resulting from the special circumstances of BMT, the diagnosis may have been missed in some similar cases and prevalence of NMS might be higher than is recognized. Early recognition of NMS is vital. In addition to discontinuation of the causative drug, administration of bromocriptine and/or dantrolene may sometimes be needed. 5, 10 NMS represents an uncommon but prognostically important factor in transplant recipients.
